RetinalGenix Technologies (RTGN) Free Cash Flow Growth (3y) (2023 - 2026)
RetinalGenix Technologies (RTGN) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 9.23% |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | -12.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.08% |
| Dec 31, 2025 | -56.85% |
| Sep 30, 2025 | -20.77% |
| Jun 30, 2025 | -138.01% |
| Mar 31, 2025 | -24.60% |
| Dec 31, 2024 | 13.76% |
| Sep 30, 2024 | -5.10% |
| Jun 30, 2024 | 18.20% |
| Mar 31, 2024 | 26.43% |
| Dec 31, 2023 | 7.94% |